Xenon Pharmaceuticals IncXENE
Scheduled
Xenon Pharmaceuticals Inc Wells Fargo 21st Annual Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- The company is preparing an NDA filing for azathiopril, an anti-seizure medication (ASM) for focal onset seizures (FOS).
- Clinical trials have studied four doses: 10, 15, 20, and 25 milligrams, with robust efficacy across all doses and best efficacy at 25 mg.
- Adverse event profiles vary by dose, with more CNS-related events at 25 mg and placebo-comparable rates at 10 mg.
- The epilepsy market has over 20 approved medications, mostly generics, with only one branded drug, Excopri (Sinobamate), priced around $15,400 annually.
- The company plans flat pricing for azathiopril, aiming for a premium price above $15,000-$18,000, reflecting its novel potassium channel modulator mechanism and strong clinical benefit.
- The initial launch will target epileptologists treating patients with difficult-to-control seizures, expanding later to general neurologists and primary care providers.
- The commercial sales force in the US is expected to be about 75 reps plus 150 total commercial staff, supported by 8-10 medical science liaisons (MSLs).
- The company plans to use a specialty pharma distribution model to improve patient access, reduce prescription abandonment, and facilitate prior authorization processes.
- Label expansion efforts include studies in primary generalized tonic clonic seizures (PGT-CS) and pediatric populations, with ongoing pediatric work and additional formulations planned.
- The Xtol 3 study is a global phase 3 trial including US, European, and Japanese patients, designed to support regulatory submissions in multiple regions.
- In depression, the ex novo 2 trial is ongoing, with a clinically meaningful HAM-D17 score separation of about two points considered significant; the company sees a strong unmet need despite recent advances in treatment-resistant depression.
- Epilepsy trials included patient-reported outcomes on depression but were not enriched for active depressive episodes, showing mood neutrality without irritability or aggression side effects.
- The company is advancing a second Nav 1.7 inhibitor (1701) for pain, targeting acute pain proof-of-concept studies next year, with plans to explore chronic pain indications later.
- Nav 1.7 is a validated target with a strong genetic basis; 1701 offers selectivity and favorable pharmacological properties compared to prior compounds.
- The acute pain market is challenging due to opioid competition, but the company sees potential to replicate successes seen by Vertex and Latigo with sodium channel inhibitors.
- Chronic non-opioid analgesics represent a large commercial opportunity, with the company evaluating whether to develop acute and chronic pain programs sequentially or in parallel.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring